Clinical Trials
2 trialsNCT02979821 2018-05-24
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Korean Association for the Study of Targeted Therapy
Phase 2 Completed
NCT01819428 2016-03-01
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
National OncoVenture
Phase 2 Terminated